Gregory Bacon and Harry Taylor
The Association of the British Pharmaceutical Industry (ABPI) published a position paper last week on Brexit and life sciences, which it produced together with 10 other associations representing the life sciences industry in Europe and the UK.
The ABPI notes that it is “encouraged by the breakthrough” in the first phase of the Brexit negotiations, and that “the regulation, trade and supply of medicines must be a priority” for the UK government in the negotiations’ second phase.
In particular, the position paper calls for “mutual recognition of regulatory activities and quality testing” and alignment of EU and UK intellectual property systems. In this regard, the position paper argues that the Member States participating in the Unified Patent Court (UPC) Agreement should “explore possible ways” for the UK to remain a part of the UPC system after Brexit.
Finally, the ABPI considers the agreement of transitional arrangements for the UK’s exit from the EU to be “critical in ensuring there is minimal disruption to patients receiving medicines” after Brexit. The position paper follows the recent announcement that the European Medicines Agency, which currently employs 900 staff in London, will relocate to Amsterdam before April 2019.